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Role of endothelin in the pathophysiology of renal ischemia-reperfusion
in normal rabbits. The present study addressed the acute effects of
endothelin-1 on renal function and neutrophils accumulation in the setting
of in vivo severe (60 mm) acute ischemia/reperfusion. Ischemia/reperfu-
sion decreased renal functional parameters and increased renal neutrophil
accumulation and medullary congestion. All these parameters markedly
improved with the intrarenal administration of anti-endothelin-1 anti-
serum. Comparatively, the intrarenal infusion of endothelin-1 decreased
renal function and increased neutrophil accumulation. Abnormalities in
renal histology were, however, less pronounced than with ischemia/
reperfusion. In experiments using rabbit isolated perfused kidneys, endo-
thelin-1 induced the accumulation of labeled neutrophils. This accumula-
tion was similar to that observed in kidneys obtained after 60 minutes of
ischemia plus 60 minutes of reperfusion. Both endothelin and ischemia/
reperfusion effects were counteracted by an anti-endothelin antibody. In
further in vitro studies, we found that endothelin-1-induced the expression
of the CD18 antigens on the neutrophil surface. In subsequent experi-
ments based on this effect of ET-1 on CD18 antigens, a blockade of both
ischemia/reperfusion-induced and endothelin- 1-induced neutrophil accu-
mulation was obtained by infusion an anti-CD18 antibody. In conclusion,
our experiments disclosed the critical role of endothelin-l as a major
promoter of early neutrophil accumulation after ischemia/reperfusion,
which occurred through an integrin-mediated mechanism.
from our and other laboratories amply supports the existence of a
relevant role of ET-1 in renal ischemia [10—14].
In the past two years, several effects of ET-1-related mecha-
nisms have been described as neutrophil properties, namely, Ca2
mobilization [15], nitric oxide (NO) and O2 production [16, 17],
adhesion to endothelial cells and heart tissue [18], aggregation
[19] and neutrophil-dependent platelet activation [20]. However,
data are needed examining the effects of ET-1 on neutrophils in
pathological circumstances. In the case of ischemic injury, in-
creased ET-1 formation and neutrophils accumulation are coex-
istent phenomena [21, 22], and the presence of a mechanistic
relationship between them is worthy of exploration.
The aim of the present experiments was to test the hypothesis
that ET-l has a relevant role on hR-related renal neutrophil
accumulation. The complementary hypothesis, that the effects of
kidney-borne ET-1 may extend to the systemic level, also was
tested by examining neutrophil accumulation in the hearts of
animals with kidney hR or intrarenal ET-1 infusion.
Methods
In vivo studies
Ischemia/reperfusion (I!R) is a leading cause of organ damage
in diverse clinical circumstances [reviewed in 1—3]. The mecha-
nisms proposed to explain the hR-induced damage include an-
oxia, neutrophil accumulation and release of oxygen free radicals
during reperfusion and lytic enzymes [13]. Several approaches
have been tried, such as: to restore blood flow by using vasodila-
tory drugs [4]; to reduce the effects of oxygen free radicals by
means of scavenging agents [5, 61; and to diminish neutrophil
accumulation or block the activation of neutrophil-borne, tissue-
damaging enzymes, by using antibodies against adhesive integrins
or protease inhibitors [7, 8].
In recent years, considerable information has been gathered on
the role of the vasoconstricting peptide, endothelin-1 (ET-1), in
circulatory regulation [reviewed in 9]. Experimental evidence
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Animals instrumentation and experimental procedures. The study
protocols were approved by the Institutional Review Board and
performed according the international conventions on animal
experimentation. All the in vivo and perfused organ studies were
performed in male New Zealand rabbits, weighing 2.5 to 2.8 kg.
All the animals had free access to food and water. For in vivo
experiments, after sodium pentobarhital anesthesia (100 mg/kg
body wt, i.p.), rabbits underwent femoral vein and artery cannu-
lation and the abdominal cavity was midline opened. A continu-
ous physiological saline solution (PSS, in mM: NaCI 137, KCI 2.6,
K}12P04 1.5, NaH2PO4 8, glucose 5.6, pH 7.4, 37°C, 0.25 ml/min)
infusion was started and maintained throughout the entire exper-
iment. After the extraction of blood samples for measuring
femoral and right renal vein ET-1 plasma levels, right uninephrec-
tomy was performed, the first branch of the renal artery and
ureter were cannulated and heparin (100 lU. kg body wt, i.v.) was
administered. The extracted kidneys were frozen in liquid nitro-
gen, to serve as baseline controls of myeloperoxidase (MPO)
activity. Mean arterial pressure was continuously monitorized
(Letica polygraph; Scientific Instruments, Madrid, Spain) and
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body temperature was monitorized by an intrarectal electrical
thermometer (Elektrolaboratoriet, Copenhagen, Denmark) and
maintained between 36° and 37°C to avoid possible interference in
the ischemic phenomenon by temperature changes [23]. At the
end of a 45-minute equilibration period, blood samples were
taken for the determination of packed cell volume, creatinine and
electrolytes. Thereafter, the left renal artery was occluded for 60
minutes with a nontraumatic clamp, as described previously [10].
At the end of this time, the clamp was released and reperfusion
allowed for an additional 60 minutes. Once the reperfusion phase
was finished, samples for ET-1 measurement were obtained from
renal and femoral veins, the animals were killed by overdose of
anesthesia, and the kidney and heart were extracted, washed with
cold PSS and frozen in liquid nitrogen.
Measurement of renal function. Renal functional parameters
were measured as previously described [10, 24], by administrating
metoxi-['4C]-IN (CIN; loading dose, 3 .rCi/ml; infusion, 0.62
tCi/m1 in PSS, 3 ml/hr) and [3H1-PAH (loading dose, 13 tCi/ml;
infusion, 2.5 Ci/ml, 3 ml/hr). Two 30-minute urine collections
were completed, with blood sampling (150 d) done at the
beginning and end of each clearance period. [3H] and ['4C1
activities were measured using a two channel liquid scintillation
counter which corrected for the interference between isotopes.
CIN was used for calculating fractional Na excretion (FENa). Even
though important changes in the renal handling of PAH may
occur during ischemia, CPAH was used as a comparative index of
the putative changes in RPF occurring with each experimental
maneuver. The absolute values of CPAH should, however, be
considered with the caveat that hR may generate a systematic
error. Creatinine and electrolytes were measured by an automatic
analyzer (Astra IV Beckman).
Pathology studies. Kidney samples were fixed in 10% formalde-
hyde, stained with routine techniques and examined by optical
microscopy in a blinded fashion by a renal pathologist (F.M.). The
kidneys were specifically analyzed for the presence of tubular
damage and medullary congestion patterns, as suggested by Solez
et al [25] and classified using a numerical score to define the
degree of tubular damage: 0 = no damage; 1 = unicellular, patchy
isolated necrosis; 2 = tubular necrosis less than 25%; 3 = tubular
necrosis between 25 and 50%; 4 more than 50% tubular
necrosis and presence of infarcted tissue. Degree of medullary
congestion was defined by: 0 = no congestion; 1 = vascular
congestion with identification of erythrocytes by x400 magnifica-
tion; 2 = vascular congestion with identification of erythrocytes by
x200 magnification; 3 = vascular congestion with identification of
erythrocytes by X 100 magnification; 4 = vascular congestion with
identification of erythrocytes by X40 magnification.
Measurement of myeloperoxidase activity. MPO activity was
measured in animals submitted to hRwith or without the different
maneuvers detailed in the experimental protocols (see below), by
assessing the change in absorbance of o-dianisidine hydrochlo-
ride, as described [18, 26], and after homogenizing the tissues in
50 m potassium phosphate buffer, pH 6.0, containing 0.5%
hexadecyltrimethylammonium bromide. In the conditions used,
no interference could be expected from peroxidase activities other
than MPO [26]. A standard in vitro curve was constructed using
known numbers of neutrophils that showed a significant correla-
tion between the number of neutrophils and MPO activity (r =
0.92, P < 0.001).
Measurements of plasma ET-1 levels. Blood samples were ex-
tracted in cold tubes containing EDTA (0.2 M), phenyl-methylsul-
phonyl fluoride (10 M) and leupeptin (10 tg/ml), centrifuged
(3000 rpm, at 4°C for iS mm) and plasma stored at —70°C until
determinations were performed. ET-1 levels were measured by
enzymoimmunoassay (EIA; Cayman Chemical, MI, USA). The
sensitivity of the assay was 7.8 pg/mi and the intra- and interassay
variations were below 5.0 and 15%, respectively.
Experimental protocols for the in vivo studies. All of the solutions
were freshly prepared in sterile PSS (37°C, pH 7.4), immediately
before using. The different agents or vehicle were given as
detailed below, by continuous intrarenal infusion (3.75 mi/hr)
through the retrograde cannulated branch of the renal artery. All
the infusions began immediately prior (2 mm) to the initiation of
reperfusion and lasted during the entire reperfusion phase. In the
animals receiving no pharmacological agents, a similar volume of
the vehicle was administered.
The rabbits were assigned to one of the following protocols.
Study I: (a) hR group. A group of animals (N = 10) was
submitted to hR as detailed above, receiving only vehicle infu-
sions.
(b) Anti-ET-1 group. To study the potential role of ET-1 in the
initiation and maintenance of ischemic acute renal failure, a
similar hR procedure was carried out with the intrarenal admin-
istration of either anti-ET-1 monoclonal antibody (MoAb) (Pen-
insula Laboratories, mc, London, UK; cross-reaction 100% with
ET-1, less than 0.01% with ET-2 and ET-3, and 1% with porcine
and human big ET-1, 1:10000; N = 6) [101. The use of the
anti-ET-1 MoAb was preferred instead of using the ET-1 antag-
onist BQ-123 for two reasons: (1) BQ-123 does not block ET-B
receptors, which are instrumental in the renal vasoconstricting
response of ET-1 [27]; instead, the MoAb blocks all the effects of
ET-1; and (2) an effect of BQ-123 has been described as a blocker
of angiotensin Il-mediated effects, which could be a source of
misinterpretation [281.
(c) Nonspecific IgG group. A nonspecific IgG (1:10000, N = 3)
that had no cross reactivity with any of the endothelin isoforms
was used for control purposes.
(d) Dopamine group. Dopamine, a non-NO-mediated vasodila-
tor, was used at renal vasodilating dose (2 jtg/kg body wt/min, N =
3) to assess whether any effect of the maneuvers mentioned above
could be unspecifically attributed to vasodilation. In previous
set-up experiments, we found that in control animals, this dose of
dopamine increased CIN and CPAFI by 30 2 (P < 0.01) and 47
3% (P < 0.005), respectively (Cernadas et al, unpublished re-
sults).
Study II. To further clarify the role of ET-1 on the pathophys-
iological mechanisms involved in I/R, the response to 60 minutes
of intrarenal ET-1 infusion (0.027 jtg/min, N = 7) was examined.
In this case, the kidneys were not submitted to renal artery
clamping and the ET-1 infusion period substituted for the renal
ischemia.
in vitro studies
Neutrophils preparation. Rabbit neutrophils were obtained from
peripheral blood by Ficoli-hypaque centrifugation, as previously
described [151. Neutrophils (95% pure, 98% viable by trypan blue
exclusion) were resuspended (5 X IO cells/mi) in 3 ml Hepes
buffer containing, in mM: 131 NaCI; 4.7 KCI; 5 glucose and 20
Hepes, pH 7.4 and 2 Ci/ml Na2[51Cr] 04. After incubation
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(37°C, 60 mm) the cells were washed three times in Hepes and
resuspended in Krebs-Henseleit buffer (in mM: NaC1 118, KC1 4.7,
KH2PO4 1.2, MgSO4 1.2, C12Ca 2.5, NaHCO7 25, pH 7.4) at a
density of 5 >< 106 cells/mi.
The monoclonal antibodies anti-CD18 MoAb (TSI/18) and
P3X63 used in the in vitro studies described below were provided
by Prof. F. Sanchez Madrid (Hospital de Ia Princesa, Universidad
Autónoma, Madrid, Spain) and prepared as reported [29]. P3X63
myeloma culture supernatant was used as a negative control. No
in vivo studies could be done using the TS 1/18 MoAb because of
its limited availability.
Flow cytometly experiments. In an effort to clarify whether the
effects of ET-1 on neutrophil accumulation were related to
changes in the surface expression of adhesive integrins. For this
purpose, rabbit neutrophils were incubated with ET-1 (10—v M)
for 30 minutes. After the incubation was completed, the neutro-
phils were incubated with the anti-CD 18 MoAb followed by a
second incubation with a fluorescein isothyocyanate-conjugated
goat anti-mouse IgG (The Binding Site, Birmingham, UK). The
fluorescence was measured as described [18] by using an EPICS
flow cytometer/sorter (Coulter) at 480 nm excitation and 520 nm
emission. A minimum of 5000 cells were analyzed for each
sample. The data were displayed as one-parameter histograms
plotting the logarithm of the fluorescence signal versus the cell
number.
Isolated perfused kidney experiments. Experiments on isolated
perfused kidneys were done as an in vitro probe for neutrophil
accumulation in renal tissue. Perfusion of isolated rabbit kidneys
was carried out according to modifications of the methods of
Maack [30] and Little and Cohen [31]. Briefly, after a surgical
preparation procedure similar to described above, the left kidney
was perfused in situ (PSS infusion, 4°C, arterial 22-gauge needle)
and rapidly removed and placed into a siliconyzed glass beaker
(37°C, 95% 02, 5% C02) which contained Krebs-Henseleit
solution (pH 7.4) supplemented with 5 m glucose, 5% fatty-acid
free bovine serum albumin and 10 mI/liter of a 20 amino acid
mixture (NitrOgeno 10; Ibys, Madrid, Spain). Flow was initially set
at 10 ml/min and graduated to keep pressure at 100 mm Hg. A
peristaltic pump (Harvard) was used for carrying out the perfu-
sion; the perfusion system was closed, therefore allowing the
perfusate to recirculate. Experiments were performed as follows:
(a) in kidneys from normal animals, ET-1 (0.013 JIg/mm in
Krebs-Henseleit solution, N = 4) or vehicle (N = 4) were
perfused for 30 minutes at a rate of 0.1 mi/mm. The ET-i dose
was selected according to previous reports, which have shown that
doses in the above-mentioned range did not produce significant in
vivo vasoconstrictor effects [32]. Two minutes after the beginning
of the ET-1 infusion, 51Cr-labeled rabbit neutrophils in sterile
Krebs buffer (8 x 106 in 0.5 ml, 79,995 10,354 cpm/8 >< 10'
cells) were injected as a bolus. The experiments were stopped by
washing out the non adherent neutrophiis with fresh Krebs-
Henseleit buffer, the kidneys were homogenized in 10% TCA and
radioactivity counted. (b) Experiments similar to those described
in (a) were done, preincubating (10 mm) the 51Cr-laheled neu-
trophils with the MoAb TSI/18 or with the nonspecific antibody,
P3X63. (c) Kidneys extracted after 60 minutes I/R were submitted
to identical procedures. Infusions were carried out of either
vehicle alone (N 4), anti-ET-1 (N = 4) or nonspecific IgG (N
3). Further studies (see below) were done in kidneys submitted to
identical experimental procedures, to examine the role of anti-
Table 1. Renal functional parameters after 60 mm I/R in
uninephrectomized rabbits treated with different agents
CIN CPAH
ml/min
Baseline
Post-I/R
I/R+antj-ET-1
IIR+IgG
3.76 0.33
0.39 0.13°
2.58
0.47 0.05°
11.22 2.55
1.01 0.55k'
8.52 2.30°'
1.31 0.09
Values are mean SCM of two periods of 30 mm each, after 60 mm
ischemia/60 mm reperfusion (N = 10 animals) or in the presence of
anti-ET-1 antibody (1:10000; N = 6) or nonspecific IgG (N = 3).
Abbreviations are: ET-1, endothelin-1; I/R, 60 mm ischemia/60 mm
reperfusion. A mean vlaue of all the animals was used for the baseline data
represented in this table. This was done because no significant differences
in the baseline CIN or CPAH were detected between the different groups in
the baseline measurements, P = NS, data not shown).
Significant differences with respect to the baseline
6Significant differences with respect to ischemia alone
ET-1 in the functional behavior of the isolated perfused kidney
preparation.
To discard a nonspecific trapping of neutrophils induced by a
putative undetected vasoconstrictor effect of ET-1, two additional
experiments were carried out: (a) neutrophils were incubated with
the MoAb against the CD18 antigen, TSI/18, from 10 minutes
before and throughout their infusion in the renal circulation. (b)
To rule out any possible nonspecific interaction between anti-
human TS1/18 and rabbit neutrophils, experiments were carried
out using human neutrophils preincubated with TS1/18 before
infusing them into the isolated rabbit kidney (N = 3). Human
neutrophils were prepared and labeled following the same proce-
dure than for rabbit neutrophils.
Additional experiments were done to determine the role of
ET-1 antagonism by the ET-1 antibody in the functional behavior
of the isolated perfused kidney preparation. For this purpose,
experiments identical to those described in item 3 were per-
formed, with the modifications that both renal vein and ureter
were cannulated in addition to the renal artery, urine was
collected every 20 minutes and inulin (Sigma, 250 mg/liter) was
added to the perfusate. Infusions were carried out of either
vehicle plus nonspecific IgG (N = 3) or anti-ET-1 (N = 3) in
kidneys extracted after 60 minutes I/R; kidneys extracted without
I/R (N = 3) were used for control purposes. Inulin was measured
in simultaneous perfusate and urine samples by the anthrone
method.
Statistics
Values are expressed as mean SEM. Changes in variables
between groups were analyzed by ANOVA and subsequent
Scheffé's and Fisher's test. Differences between two groups were
evaluated by the unpaired Student's t-test and differences between
two periods of the same animals by the paired Student's t-test. A
value of P < 0.05 was considered significant.
Results
In vivo experiments
Study I. (a) Renal functional studies. The occlusion of the renal
artery for 60 minutes in control uninephrectomized rabbits in-
duced a decrease of CIN, CPAH (Table 1) and urinary volume
(UV), and an increase of FENa in the first hour following
unclamping of the renal artery (P < 0.001 with respect to the
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UV
pJ/min
V
p.Eq/min
FEN.
%
Baseline 37.08 0.28 5.70 0.9 0.8 0.3
Post-hR 7.50 0.25 5.43 1.5 9•4 3.4k'
1/R+anti-ET-1 53.07 l.48°' 13.3 3.15' 3•7 06ab
I/R+IgG 10.24 0.22 7.5 1.35 10.2 1.9
Values are expressed as mean SEM, after 60 mm ischemia/60 mm
reperfusion (N = 10) or in the presence of anti-ET-1 antibody (1:10000, N
6) or nonspecific IgG (N = 3). Abbreviations are: UV, urinary volume;
UNaV, urinary sodium excretion; FENU, fractional sodium excretion; I/R,
60 mm ischemia/60 mm reperfusion.
Significant differences (P < 0.001) with respect to the baseline
' Significant differences (P < 0.05) with respect to JR alone
baseline; Table 2). A recovery to near baseline values (Table 1,
P < 0.001) of the post-hR decrease in CIN and CPAH was obtained
with the infusion of the anti-ET-1 antibody (1:10000). The anti-
ET-1 antibody infusion also induced significant changes on diure-
sis, natriuresis and FEN with respect to l/R alone (Table 2). No
effects on CIN, CPAH, urinary volume or Na excretion were
detected with the administration of the nonspecific antibody (P =
NS; Table 1).
The experiments using dopamine demonstrated only a minor
effect on CIN (0.79 0.18 mI/mm, P = NS with respect to hR
alone) and a moderate effect on CPAI{ (2.64 0.94 mI/mm, P <
0.05 with respect to hR alone), UV (50.9 5.4 j.d/min, P < 0.05
with respect to hR alone) and UNUV (9.9 1.8 j.tEq/min, P < 0.02
with respect to hR alone). The FENa was, however, in a range
similar to that in h/R (8.9 0.9%, P = NS). No major changes in
systemic mean arterial pressure were observed with either of the
experimental maneuvers (P = NS; data not shown).
(b) Histology studies. I/R provoked a significant degree of
medullary congestion and tubular damage, which was significantly
improved by the infusion of the ET-1 antibody and not by the
nonspecific IgG (Fig. 1). Histologic scores at baseline are not
represented, since they were not different from zero. No signifi-
cant increase in neutrophil accumulation was found at optical
microscopy with any of the experimental maneuvers (P = NS for
all the samples with respect to the nonischemic controls, data not
shown). In view of the MPO findings shown in the next paragraph,
multiple samples from differents areas of the kidney were used to
further ascertain the reliability of this observation.
(c) Measurement of myeloperoxidase activity. An increased renal
MPO activity, a marker of neutrophil accumulation, was observed
after hR (Fig. 2). This increase was blunted by the administration
of the anti-ET-1 antibody infusion (1:10000; Fig. 2). An increased
MPO activity was also detected in the hearts of the animals with
renal l/R (Fig. 2). Moreover, no effect on the increased MPO
activity was observed in the animals submitted to hR infused with
dopamine (2 jig/kg body wt/min, N = 3; MPO, 2.4 0.4 vs. 2.1
0.2 U!g tissue in hR and hR + dopamine, respectively; P = NS).
This phenomenon was also inhibited in the presence of the anti-ET-1
antibody infusion (1:10000; Fig. 2). No significant effects were
detected with the administration of nonspecific IgG (1:10000; Fig. 2).
Moreover, no effect on the increased MPO activity was detected in
the animals submitted to hR and infused with dopamine (2 jig/kg
body wt/min, N = 3; MPO, 2.4 0.4 vs. 2.1 0.2 UIg tissue in hR
and I/R + dopamine, respectively; P NS).
No changes in baseline MPO activity were observed in either
Kidney Heart
Fig. 2. Effects of anti-endothelin-J antibody and nonspecific IgG adminis-
Iration on the increased myeloperoxidase activity after renal hR in rabbits.
p < 0.05 with respect to increased renal and heart myeloperoxidase
activity.
the kidney or the heart of sham-operated rabbits not submitted to
hR (MPO activity 0.47 0.01 U/g kidney tissue and 0.17 0.04
[Jig heart tissue, N = 3, P = NS). Moreover, no changes in MPO
activity were detected in similar sham-operated animals submitted
to an anti-ET-1 antibody infusion (P = NS, N = 3; data not
shown).
(d) Measurements of ET-1 plasma levels. The plasma FT-I levels
in the renal vein were in the limit of detection in control
conditions (9.3 1.2 pg/ml), hut increased significantly after hR
in vehicle-treated rabbits (48.2 6.8 pg/mI, P < 0.01 with respect
Table 2. Diuresis and natriuresis after infusion of the anti-endothehin-l
antibody or nonspecific IgG in rabbits
Medullary congestion Tubular damage
3.5
3
a)C)
E
Ca0
C
2 2
0
a)
1.5
(I)
0
0)0
0
(I)I
0.5
0
Fig. 1. Histologic score of vascular medulla,y congestion and tubular dam-
age after 60 minutes of ischemia/60 minutes of reperfusion in rabbits. Effects
of anti-FT-i infusion. * Represents significant differences (P <0.01) with
respect to hR alone. Abbreviations are: h/R, 60 minutes of ischemia/60
minutes of reperfusion; ET-1, endothelin-1.
3 0.6
a)
2.5
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>
1.5 0.3
a)
C,)
Ca0• 10
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CIN CPA11
mi/mm
Baseline 4.38 0.34 12.30 0.67
ET-1 1.27 0.22a 4.72 1.05
UV
p1/mm
UN. V
p.Eq/min
FEN..
%
Baseline 37.08 0.28 5.70 0.9 0.8 0.3
ET-1 13.03 0.24 0.31 0.09a 0.2 o.o5
to the baseline). Also, a similar increase was detected in systemic
venous blood (baseline 7.9 1.5; hR 45.7 4.7 pg/mI, P < 0.01).
No differences were observed in renal vein ET-1 between vehicle-
and anti-ET-1 antibody-treated animals (42.2 7.5 pg/mI).
Study II
Renal functional studies. The intrarenal ET-.1 infusion caused a
significant reduction of CIN and CpAI (Table 3), which was
blocked by the anti-ET-1 antibody (Table 3). Also, a reduction in
urinary volume and Na excretion was observed, with increased
FENa (Table 4). No changes in systemic arterial pressure were
detected with the administered dose (0.027 ,iLg/min) of ET-1
(increase in mean arterial pressure 4 1.8 mm Hg, P = NS).
Renal histology. In spite of the intense functional changes
observed after ET-1 infusion, only a moderate degree (1.9 0.4
histologic score, N = 4, P < 0.02 with respect to the control
animals) of medullary congestion was detected. No signs of
tubular damage were detected in any instance (score NS with
respect to control).
Measurement of myeloperoxiduse activity. The intrarenal admin-
istration of ET-1 significantly increased MPO activity within the
rabbit kidney (Fig. 3). A significant increase of MPO activity in the
rabbit heart was also detected in these conditions (Fig. 3).
In vitro experiments
Study IV Flow cytometly studies. The flow cytometry experi-
ments showed a 34.7 3.6% increase in CD18 expression in ET-1
(10-v M)-treated with respect to untreated neutrophils (Fig. 4).
Neutrophil accumulation in the isolated, perfused kidney. ET-1
infusion markedly increased the accumulation of rabbit neutro-
phils on the isolated, perfused rabbit kidney (neutrophil accumu-
lation with vehicle infusion, 1.5 X 106 1.6 x i0; with ET-1
infusion, 4.2 x lO 3.8 x i05 neutrophils; N = 5 each; P <
0.01). No changes in the renal perfusion pressure were evident
with the dose of ET-1 used (0.013 j.rglmin, perfusion pressure
100 21 and 104 26 mm Hg, in the absence or presence of
ET-1, respectively; P = NS). TS1/18 inhibited ET-1-induced
Kidney Heart
Fig. 3. Myeloperoxidase activity (U/g tissue) in renal and heart tissue from
intrarenal ET-] -infused rabbits (0.027 pg/miss, N 7). Results are repre-
sented as mean SEM. *p < 0.05 with respect to baseline. #p < 0.05 with
respect to ET-1 infusion. Abbreviations are: ET-I, endothelin-1; I/R, 60
minutes of ischemia/60 minutes of reperfusion.
Relative fluorescence intensity, log
Fig. 4. Flow cytometiy analysis of the expression of CDI8 antigen on the
rabbit neutrophil suiface, unstimulated (I), or stimulated with io M ET-1
(2). The Figure reproduces the trace of one typical experiment. Abbrevi-
ation is ET-1, endothelin-1.
neutrophil accumulation by 75 15% (P < 0.01), whereas only
1.2 0.8 inhibition was obtained by preincubating the neutrophils
with the non specific MoAb P3 >< 63 (P = NS).
ET-l stimulated human neutrophil accumulation in a similar
degree than observed with rabbit neutrophils (increase of human
neutrophils accumulation 3.01 x 106 3.01 X 1O neutrophils,
N 4, P < 0.05). This effect was inhibited (73 12% inhibition,
N = 3, P < 0.05 with respect to ET-1 alone) by the simultaneous
infusion of TS1/18.
An increased accumulation of 51Cr-labeled neutrophils was also
observed in isolated, perfused kidneys extracted after one hour of
in vivo ischemia, followed by one hour reperfusion (% accumula-
tion 55.3 3%, N = 3 hR kidneys; 28.2 4, N = 3 kidneys from
sham operated animals). This increased accumulation was inhib-
ited (83.5 5% inhibition, P < 0.05) by the administration of
anti-ET-1 antibody (1:10000) in the medium containing the
51Cr-labeled neutrophils. No inhibition of the hR-stimulated
neutrophil accumulation was found with the nonspecific IgG.
Table 3. Functional parameters after intrarenal endothelin-1 infusion
in rabbits
Values are expressed as mean SCM of two periods of 30 mm each,
after ET-l infusion (0.027 jsg/min; N = 7). Abbreviation is ET-1,
endothelin-1.
a Significant differences (P < 0.001) with respect to the baseline
Table 4. Diuresis and natriuresis after intrarenal ET-I infusion in
rabbits
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Values are expressed as mean SCM, after ET-1 infusion (0.027 /sg/min;
N = 7). Abbreviations are: UV, urinary volume; UNaV, urinary sodium
excretion; FENa, fractional sodium excretion.
a Significant differences (P < .001) with respect to the baseline
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In further studies assessing the functional characteristics of
kidneys submitted to identical experimental procedures but with-
out the infusion of labeled neutrophils, we obtained the following
data: as predictable, hR provoked a marked reduction of CIN
(78.5 5.8% reduction, P < 0.01 with respect to the control,
non-hR kidneys). This effect was markedly blocked in the pres-
ence of the anti-FT-I antibody (16.4 5.6% reduction, P = NS
with respect to the control, P < 0.01 with respect to the hR +
nonspecific IgG). The mean value of C1 in the control, non-hR
kidneys was 367 37 .d min g1 wet kidney weight.
Moreover, different characteristics of intrarenal resistances were
observed in the hR kidneys compared to the hR kidneys perfused
with anti-ET-1 antibody and control kidneys, namely, the mean
flow necessary for maintaining 100 mm Hg intrarenal pressure
throughout the 60-minute perfusion period was 4.05 0.7 mI/mm
in hR versus 8.9 0.9 mi/mm in hR + anti-ET-1 antibody versus
10.8 0.3 ml/min in controls, P < 0.05 of hR with respect to the
other two groups.
Discussion
The rationale for the present study was based on previous
evidence that separately implicated ET-1 as a relevant mediator in
renal hR [10, 11] and in neutrophil activation [18, 20]. The
administration of the anti-ET-1-antibody revealed that ET-i was
a crucial mediator not only of renal functional derangement but
also of post-hR renal neutrophil accumulation. The specificity of
this effect and the significant role of FT-i-related expression or
neutrophil adhesive integrins were supported by the results ob-
tained with the in vivo ET-1 infusions and flow cytometry isolated
perfused kidneys experiments.
The accumulation of neutrophils after hR is a well character-
ized phenomenon in different organs [3, 7, 8, 33—35]. At the
present time, the prevalent opinion indicates that neutrophils may
have a role in aggravating the severity of myocardial and mesen-
teric ischemia [33—35], but their pathogenetic potential in renal
hR is still controversial. Data have been obtained that either deny
[7, 36] or favor [8, 37] the importance of neutrophils in renal h/R,
and the debate is still alive. Our experiments suggested that a
significant neutrophil accumulation occurred in the kidney in the
first hour after hR. This phenomenon was evidenced by the MPO
method but not by the histological techniques. This apparent
discordance between both methods therefore suggests that 60
minutes of hR might be too short a time to detect a significant
increase in neutrophil infiltration in the microscopical prepara-
tions. Accordingly, in this setting MPO might be a more sensitive
technique. Similar to our findings, Thornton et al observed no
histological evidence of neutrophil infiltration after a 60-minute
ischemic period [7]. Moreover, Solez, Kramer and Fox have found
that a significant presence of leukocytes could not be demon-
strated by histology up to 36 hours after experimental acute renal
failure [25]. The validity of the MPO method in this case is
supported by the specific and high concentration of MPO within
the azurophil bodies of the granulocytes, which makes any other
resident or macrophage type cell unlikely to be responsible for any
increase in MPO activity. An explanation for this apparent
dissociation between the histological and MPO findings can be
derived from data recently published by Saeki et al [38], who
found that in conditions of neutrophil activation and massive
degranulation, MPO is released outside the neutrophils and
bounds to kidney cellular membranes. In these conditions, de-
granulated neutrophils would be not longer identified by histolog-
ical techniques, whereas MPO activity would be readily quantified
by enzymatic assays.
It is necessary to re-emphasize, however, that our experiments
were not specifically aimed at analyzing the role of neutrophils in
the outcome of renal hR. In fact, the present studies were
circumscribed only to examine the role of ET-1 and the mecha-
nisms intervening in neutrophil accumulation during renal hR. In
this regard, three aspects appeared with a defined profile: (a) the
same maneuver that interfered with the renal functional conse-
quences of h/R, namely, the anti-ET-l antibody infusion, blocked
neutrophil accumulation; (b) the specificity of this effect was
demonstrated by several experimental findings, namely, the effect
of the TSi/18 antibody in the in vitro perfusion experiments, the
increase in CD18 expression by ET-1 detected in the flow
cytometry studies and the lack of effect of the renal vasodilator,
dopamine, in MPO levels. (c) ET-1 infusion per se favored the
neutrophil accumulation in the kidneys, as we have previously
observed in heart tissue [18]. The experiments showing that the
anti-FT-I antibody blocked the post-hR neutrophil accumulation
strongly suggested that ET-1 was a significant mediator of this
phenomenon. The renal functional improvement observed in the
same experiments further confirms that the anti-ET-1 antibody
was effective in modifying the immediate outcome of renal h/R,
even in the isolated perfused kidney. The findings on neutrophils
adherence should, however, be mainly traced to an integrin-
mediated mechanism, on the basis of the effect of the anti CD18
antibody. A hemodynamic-related mechanism could, however, be
also operative, as judged by the results obtained with FT-i
blockade by the anti-ET-1 antibody. Of additional interest are the
data showing an increased neutrophil accumulation in the hearts
of rabbits with renal hR and ET-i infusion. The results obtained
with intrarenal ET-1 and anti-FT-I antibody infusions demon-
strated a distant effect of ET-i generated in the kidney during hR.
The potential pathophysiological implications of this finding need
to be specifically addressed. In fact, these results suggest that
myocardial effects may occur during ischemic episodes in distant
organs. The possibility for the observed myocardial neutrophil
accumulation to be pathologically relevant should be considered
on the light of the proposed role of neutrophils on deranged
myocardial function [39]. Preliminary data from Atanasova et al
[40] have suggested that, in circumstances of NO-generation
inhibition, renal hR may provoke systemic circulatory complica-
tions.
The present results expand to neutrophil-mediated effects the
possible actions of ET-1 as a pathogenetic agent in early hR.
However, since increased release of FT-i can be expected as long
as post-hR endothelial persists, this finding may provide a clue to
understanding the pathophysiological sequence leading to sus-
tained neutrophil accumulation and prolonged post-ischemic re-
nal damage, and perhaps for neutrophil infiltration in pathological
situations involving ET-1 release other than hR.
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Appendix
Abbreviations are: ET-1, endothelin-1; FEN, fractional sodium excre-
tion; GFR, glomerular filtration rate; MPO, myeloperoxidase; PSS, phys-
iological sterile saline; UNaV, urinary sodium excretion; UV, urinary
volume.
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